BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 2020;6:1. [PMID: 31911624 DOI: 10.1038/s41537-019-0090-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 72] [Article Influence: 23.5] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Y, Meyerowitz-katz G, Bramwell S, Jayaballa R, Assur Y, Vasani D, Ganapathy R, Maberly G, Brakoulias V. Evaluating the Effectiveness of Joint Specialist Case Conferences in Improving Diabetes Control in Patients With Schizophrenia on Clozapine. J Nerv Ment Dis 2022;Publish Ahead of Print. [DOI: 10.1097/nmd.0000000000001590] [Reference Citation Analysis]
2 Mishra A, Reeta KH, Sarangi SC, Maiti R, Sood M. Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial. Psychopharmacology (Berl) 2022. [PMID: 36069950 DOI: 10.1007/s00213-022-06225-2] [Reference Citation Analysis]
3 Lappin JM, Davies K, O'donnell M, Walpola IC. Underuse of recommended treatments among people living with treatment-resistant psychosis. Front Psychiatry 2022;13:987468. [DOI: 10.3389/fpsyt.2022.987468] [Reference Citation Analysis]
4 Ben-Azu B, Adebayo OG, Jarikre TA, Oyovwi MO, Edje KE, Omogbiya IA, Eduviere AT, Moke EG, Chijioke BS, Odili OS, Omondiabge OP, Oyovbaire A, Esuku DT, Ozah EO, Japhet K. Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice. Metab Brain Dis 2022. [PMID: 36057735 DOI: 10.1007/s11011-022-01075-5] [Reference Citation Analysis]
5 Matsuzaka Y, Noguchi M, Kanamura S, Maeda K, Hisano T, Tanaka D, Ando Y, Yamamoto T, Morimoto Y, Ozawa H, Otsuka T. Combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report. Neurocase. [DOI: 10.1080/13554794.2022.2114838] [Reference Citation Analysis]
6 Zahid U, Mccutcheon RA, Borgan F, Jauhar S, Pepper F, Nour MM, Rogdaki M, Osugo M, Murray GK, Hathway P, Murray RM, Howes OD. The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients. Front Psychiatry 2022;13:967941. [DOI: 10.3389/fpsyt.2022.967941] [Reference Citation Analysis]
7 Cai H, Zeng C, Zhang X, Liu Y, Wu R, Guo W, Wang J, Wu H, Tang H, Ge X, Yu Y, Zhang S, Cao T, Li N, Liang X, Yang P, Zhang B. Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study. Psychiatry Res 2022;316:114762. [PMID: 35940088 DOI: 10.1016/j.psychres.2022.114762] [Reference Citation Analysis]
8 de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics. Biomolecules 2022;12:909. [DOI: 10.3390/biom12070909] [Reference Citation Analysis]
9 Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes OD. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs 2022. [PMID: 35759211 DOI: 10.1007/s40263-022-00932-2] [Reference Citation Analysis]
10 Weston-green K. Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives. Front Psychiatry 2022;13:903156. [DOI: 10.3389/fpsyt.2022.903156] [Reference Citation Analysis]
11 Casas BS, Vitória G, Prieto CP, Casas M, Chacón C, Uhrig M, Ezquer F, Ezquer M, Rehen SK, Palma V. Schizophrenia-derived hiPSC brain microvascular endothelial-like cells show impairments in angiogenesis and blood-brain barrier function. Mol Psychiatry 2022. [PMID: 35705634 DOI: 10.1038/s41380-022-01653-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Joo SW, Kim H, Jo YT, Ahn S, Choi YJ, Choi W, Park S, Lee J. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study. European Neuropsychopharmacology 2022;59:36-44. [DOI: 10.1016/j.euroneuro.2022.03.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu C, Kim W, Shen J, Tsogt U, Kang N, Lee K, Chung Y. Altered Neuroanatomical Signatures of Patients With Treatment-Resistant Schizophrenia Compared to Patients With Early-Stage Schizophrenia and Healthy Controls. Front Psychiatry 2022;13:802025. [DOI: 10.3389/fpsyt.2022.802025] [Reference Citation Analysis]
14 DeSouza DD, Tang SX, Danilewitz M. The burgeoning role of speech and language assessment in schizophrenia spectrum disorders. Psychol Med 2022;:1-2. [PMID: 35582882 DOI: 10.1017/S0033291722001325] [Reference Citation Analysis]
15 Shi H, Xu J, Lang X, Wu HE, Xiu MH, Zhang XY. Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial. Front Pharmacol 2022;13:863588. [PMID: 35559243 DOI: 10.3389/fphar.2022.863588] [Reference Citation Analysis]
16 Komatsu H, Onoguchi G, Jerotic S, Kanahara N, Kakuto Y, Ono T, Funakoshi S, Yabana T, Nakazawa T, Tomita H. Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. [DOI: 10.1038/s41380-022-01591-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wada M, Noda Y, Iwata Y, Tsugawa S, Yoshida K, Tani H, Hirano Y, Koike S, Sasabayashi D, Katayama H, Plitman E, Ohi K, Ueno F, Caravaggio F, Koizumi T, Gerretsen P, Suzuki T, Uchida H, Müller DJ, Mimura M, Remington G, Grace AA, Graff-Guerrero A, Nakajima S. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Mol Psychiatry 2022. [PMID: 35444257 DOI: 10.1038/s41380-022-01572-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Butler E, Pillinger T, Brown K, Borgan F, Bowen A, Beck K, D'Ambrosio E, Donaldson L, Jauhar S, Kaar S, Marques TR, McCutcheon RA, Rogdaki M, Gaughran F, MacCabe J, Ramsay R, Taylor D, McCrone P, Egerton A, Howes OD. Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. Br J Psychiatry 2022;:1-8. [PMID: 35438068 DOI: 10.1192/bjp.2022.47] [Reference Citation Analysis]
19 Gautam M, Sivananthan M, Cotes R, Beach S. Catatonia and Schizophrenia in a Young Man with Autism Spectrum Disorder and Clozapine-Induced Myocarditis. Harv Rev Psychiatry 2022;Publish Ahead of Print. [DOI: 10.1097/hrp.0000000000000334] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Alonso-sánchez MF, Ford SD, Mackinley M, Silva A, Limongi R, Palaniyappan L. Progressive changes in descriptive discourse in First Episode Schizophrenia: a longitudinal computational semantics study. Schizophr 2022;8. [DOI: 10.1038/s41537-022-00246-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Spark DL, Fornito A, Langmead CJ, Stewart GD. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry 2022;12:147. [PMID: 35393394 DOI: 10.1038/s41398-022-01904-2] [Reference Citation Analysis]
22 Dion-Albert L, Bandeira Binder L, Daigle B, Hong-Minh A, Lebel M, Menard C. Sex differences in the blood-brain barrier: implications for mental health. Front Neuroendocrinol 2022;:100989. [PMID: 35271863 DOI: 10.1016/j.yfrne.2022.100989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Panov G. Dissociative Model in Patients With Resistant Schizophrenia. Front Psychiatry 2022;13:845493. [DOI: 10.3389/fpsyt.2022.845493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Juza R, Vojtechova I, Stefkova-mazochova K, Dehaen W, Petrasek T, Prchal L, Kobrlova T, Janousek J, Vlcek P, Mezeiova E, Svozil D, Karasova JZ, Pejchal J, Stark H, Satala G, Bojarski AJ, Kubacka M, Mogilski S, Randakova A, Musilek K, Soukup O, Korabecny J. Novel D2/5-HT receptor modulators related to cariprazine with potential implication to schizophrenia treatment. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Brunelin J, Mondino M, Haesebaert J, Attal J, Benoit M, Chupin M, Dollfus S, El-Hage W, Galvao F, Jardri R, Llorca PM, Magaud L, Plaze M, Schott-Pethelaz AM, Suaud-Chagny MF, Szekely D, Fakra E, Poulet E. Examining transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia (STIM'Zo): a study protocol for a multicentre, double-blind, randomized sham-controlled clinical trial. Trials 2021;22:964. [PMID: 34963486 DOI: 10.1186/s13063-021-05928-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Falkai P, Dombi ZB, Acsai K, Barabássy Á, Schmitt A, Németh G. The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials. CNS Spectr 2021;:1-8. [PMID: 35012696 DOI: 10.1017/S1092852921000997] [Reference Citation Analysis]
27 Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. IJMS 2021;22:13185. [DOI: 10.3390/ijms222413185] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev 2021;132:324-61. [PMID: 34838528 DOI: 10.1016/j.neubiorev.2021.11.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
29 Eratne D, Janelidze S, Malpas CB, Loi S, Walterfang M, Merritt A, Diouf I, Blennow K, Zetterberg H, Cilia B, Wannan C, Bousman C, Everall I, Zalesky A, Jayaram M, Thomas N, Berkovic SF, Hansson O, Velakoulis D, Pantelis C, Santillo A, Li Q, Stehmann C, Cadwallader C, Fowler C, Ravanfar P, Farrand S, Keem M, Kang M, Watson R, Yassi N, Kaylor-hughes C, Kanaan R, Perucca P, Vivash L, Ali R, O’brien TJ, Masters CL, Collins S, Kelso W, Evans A, King A, Kwan P, Gunn J, Goranitis I, Pan T, Lewis C, Kalincik T; On behalf of The MiND Study Group. Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Aust N Z J Psychiatry. [DOI: 10.1177/00048674211058684] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Damiano RF, Avrichir BS, Melzer-Ribeiro DL, Sallet PC, Elkis H. Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-report. Psychiatry Res 2021;305:114248. [PMID: 34739952 DOI: 10.1016/j.psychres.2021.114248] [Reference Citation Analysis]
31 Millgate E, Hide O, Lawrie SM, Murray RM, Maccabe JH, Kravariti E. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. Psychol Med 2022;52:1-13. [DOI: 10.1017/s0033291721004128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Chauhan P, Kaur G, Prasad R, Singh H. Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy. Expert Rev Neurother 2021;:1-13. [PMID: 34654348 DOI: 10.1080/14737175.2021.1994857] [Reference Citation Analysis]
33 Neef J, Palacios DS. Progress in mechanistically novel treatments for schizophrenia. RSC Med Chem 2021;12:1459-75. [PMID: 34671731 DOI: 10.1039/d1md00096a] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Edinoff AN, Sauce E, Ochoa CO, Cross J, Cogburn M, Cornett EM, Kaye AM, Pham AD, Kaye AD. Clozapine and Constipation: A Review of Clinical Considerations and Treatment Options. Psychiatry International 2021;2:344-52. [DOI: 10.3390/psychiatryint2030026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Meftah A, Hasegawa H, Kantrowitz JT. D-Serine: A Cross Species Review of Safety. Front Psychiatry 2021;12:726365. [PMID: 34447324 DOI: 10.3389/fpsyt.2021.726365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Fond G, Garosi A, Faugere M, Campion JY, Lancon C, Boyer L, Richieri R, Guedj E. Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia. Eur J Nucl Med Mol Imaging 2021. [PMID: 34405275 DOI: 10.1007/s00259-021-05529-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Nair PC, Miners JO, McKinnon RA, Langmead CJ, Gregory KJ, Copolov D, Chan SKW, Bastiampillai T. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Mol Psychiatry 2021. [PMID: 34376825 DOI: 10.1038/s41380-021-01250-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Benrimoh D, Sheldon A, Sibarium E, Powers AR. Computational Mechanism for the Effect of Psychosis Community Treatment: A Conceptual Review From Neurobiology to Social Interaction. Front Psychiatry 2021;12:685390. [PMID: 34385938 DOI: 10.3389/fpsyt.2021.685390] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Yang KC, Liao YT, Yang YK, Lin SK, Liang CS, Bai YM. Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN). CNS Drugs 2021;35:893-905. [PMID: 34312788 DOI: 10.1007/s40263-021-00838-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Manchia M, Fontana A, Panebianco C, Paribello P, Arzedi C, Cossu E, Garzilli M, Montis MA, Mura A, Pisanu C, Congiu D, Copetti M, Pinna F, Pazienza V, Squassina A, Carpiniello B. Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics. Biomedicines 2021;9:875. [PMID: 34440078 DOI: 10.3390/biomedicines9080875] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
41 Reynolds GP. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines? J Psychopharmacol 2021;35:1030-6. [PMID: 34256637 DOI: 10.1177/02698811211026456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Aubel T. Cariprazine: Patients with Treatment-Resistant Schizophrenia. Neuropsychiatr Dis Treat 2021;17:2327-32. [PMID: 34285492 DOI: 10.2147/NDT.S315653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
43 Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry 2021. [PMID: 34257409 DOI: 10.1038/s41380-021-01200-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
44 Lähteenvuo M, Tiihonen J. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. Drugs 2021;81:1273-84. [PMID: 34196945 DOI: 10.1007/s40265-021-01556-4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
45 Kronick J, Sabesan P, Burhan AM, Palaniyappan L. Assessment of treatment resistance criteria in non-invasive brain stimulation studies of schizophrenia. Schizophr Res 2021:S0920-9964(21)00221-8. [PMID: 34183208 DOI: 10.1016/j.schres.2021.06.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Godlewska BR, Minichino A, Emir U, Angelescu I, Lennox B, Micunovic M, Howes O, Cowen PJ. Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T. Transl Psychiatry 2021;11:367. [PMID: 34226485 DOI: 10.1038/s41398-021-01477-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
47 Tendilla-Beltrán H, Flores G. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19. Gen Hosp Psychiatry 2021;71:137-9. [PMID: 34045093 DOI: 10.1016/j.genhosppsych.2021.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tkachev A, Stekolshchikova E, Anikanov N, Zozulya S, Barkhatova A, Klyushnik T, Petrova D. Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia. Biomolecules 2021;11:720. [PMID: 34064997 DOI: 10.3390/biom11050720] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Chaiyachati BH, Gur RE. Effect of child abuse and neglect on schizophrenia and other psychotic disorders. Pharmacol Biochem Behav 2021;206:173195. [PMID: 33961909 DOI: 10.1016/j.pbb.2021.173195] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
50 Notter T. Astrocytes in schizophrenia. Brain Neurosci Adv 2021;5:23982128211009148. [PMID: 33997293 DOI: 10.1177/23982128211009148] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
51 Kamalapathy P, Kurker KP, Althoff AD, Browne JA, Werner BC. The Impact of Mental Illness on Postoperative Adverse Outcomes After Outpatient Joint Surgery. J Arthroplasty 2021;36:2734-41. [PMID: 33896669 DOI: 10.1016/j.arth.2021.04.002] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
52 Park HJ, Kang J. A Computational Framework for Controlling the Self-Restorative Brain Based on the Free Energy and Degeneracy Principles. Front Comput Neurosci 2021;15:590019. [PMID: 33935674 DOI: 10.3389/fncom.2021.590019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Horne CM, Vanes LD, Verneuil T, Mouchlianitis E, Szentgyorgyi T, Averbeck B, Leech R, Moran RJ, Shergill SS. Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia. Neuroimage Clin 2021;30:102631. [PMID: 33799270 DOI: 10.1016/j.nicl.2021.102631] [Reference Citation Analysis]
54 Kang J, Eo J, Lee DM, Park HJ. A computational framework for optimal control of a self-adjustive neural system with activity-dependent and homeostatic plasticity. Neuroimage 2021;230:117805. [PMID: 33524581 DOI: 10.1016/j.neuroimage.2021.117805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Howes OD, Whitehurst T, Shatalina E, Townsend L, Onwordi EC, Mak TLA, Arumuham A, O'Brien O, Lobo M, Vano L, Zahid U, Butler E, Osugo M. The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis. World Psychiatry 2021;20:75-95. [PMID: 33432766 DOI: 10.1002/wps.20822] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 34.0] [Reference Citation Analysis]
56 Carton L, Bordet R, Montastruc F, Guilhaumou R. Towards personalized pharmacology: Antipsychotics and schizophrenia. Therapie 2021;76:137-47. [PMID: 33423786 DOI: 10.1016/j.therap.2020.12.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Kuusimäki T, Al‐abdulrasul H, Kurki S, Hietala J, Hartikainen S, Koponen M, Tolppanen A, Kaasinen V. Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders. Mov Disord 2021;36:1353-61. [DOI: 10.1002/mds.28484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
58 Leboyer M, Godin O, Terro E, Boukouaci W, Lu CL, Andre M, Aouizerate B, Berna F, Barau C, Capdevielle D, Clauss-Kobayashi J, Chereau I, D Amato T, Dubertret C, Dubreucq J, Fond G, Laouamri H, Leignier S, Lancon C, Llorca PM, Mallet J, Le Corvoisier P, Misdrahi D, Passerieux C, Rey R, Pignon B, Urbach M, Szoke A, Schürhoff F, Tamouza R; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups . Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Schizophr Bull Open 2021;2:sgab012. [PMID: 34901861 DOI: 10.1093/schizbullopen/sgab012] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 . Progress in Schizophrenia Research and Treatment. Focus (Am Psychiatr Publ) 2020;18:440-2. [PMID: 33343257 DOI: 10.1176/appi.focus.18310] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Tendilla-Beltrán H, Sanchez-Islas NDC, Marina-Ramos M, Leza JC, Flores G. The prefrontal cortex as a target for atypical antipsychotics in schizophrenia, lessons of neurodevelopmental animal models. Prog Neurobiol 2021;199:101967. [PMID: 33271238 DOI: 10.1016/j.pneurobio.2020.101967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 Cieślik P, Wierońska JM. Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery. Int J Mol Sci 2020;21:E8811. [PMID: 33233865 DOI: 10.3390/ijms21228811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Dragoi AM, Radulescu I, Năsui BA, Pop AL, Varlas VN, Trifu S. Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19. Brain Sci 2020;10:E840. [PMID: 33187329 DOI: 10.3390/brainsci10110840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
63 Shukla RP, Rapier C, Glassman M, Liu F, Kelly DL, Ben-yoav H. An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients. Electrochemistry Communications 2020;120:106850. [DOI: 10.1016/j.elecom.2020.106850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Karlović D, Silić A, Crnković D, Peitl V. Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. Hum Psychopharmacol 2021;36:e2763. [PMID: 33058260 DOI: 10.1002/hup.2763] [Reference Citation Analysis]
65 Krzystanek M, Asman M, Witecka J, Pałasz A, Wiaderkiewicz R. Selected single-nucleotide variants in GRIN1, GRIN2A, and GRIN2B encoding subunits of the NMDA receptor are not biomarkers of schizophrenia resistant to clozapine: exploratory study. Pharmacol Rep 2021;73:309-15. [PMID: 33025395 DOI: 10.1007/s43440-020-00165-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
66 Okada M, Fukuyama K, Shiroyama T, Murata M. A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43. Int J Mol Sci 2020;21:E7019. [PMID: 32987640 DOI: 10.3390/ijms21197019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
67 Chauhan P, Garg S, Tikka SK, Khattri S. Efficacy of Intensive Cerebellar Intermittent Theta Burst Stimulation (iCiTBS) in Treatment-Resistant Schizophrenia: a Randomized Placebo-Controlled Study. Cerebellum 2021;20:116-23. [PMID: 32964381 DOI: 10.1007/s12311-020-01193-9] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
68 Zhu M, Ferrara M, Tan W, Shang X, Syed S, Zhang L, Qin Q, Hu X, Rohrbaugh R, Srihari VH, Liu Z. Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China. Early Interv Psychiatry 2021;15:1010-8. [PMID: 32924286 DOI: 10.1111/eip.13046] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Limongi R, Mackinley M, Dempster K, Khan AR, Gati JS, Palaniyappan L. Frontal-striatal connectivity and positive symptoms of schizophrenia: implications for the mechanistic basis of prefrontal rTMS. Eur Arch Psychiatry Clin Neurosci 2021;271:3-15. [PMID: 32683527 DOI: 10.1007/s00406-020-01163-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
70 Martel JC, Gatti McArthur S. Dopamine receptor subtypes, Physiology and pharmacology: New ligands and concepts in schizophrenia. Front Pharmacol. 2020;11:1003. [PMID: 32765257 DOI: 10.3389/fphar.2020.01003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 41] [Article Influence: 11.5] [Reference Citation Analysis]
71 Zhuo C, Xiao B, Chen C, Jiang D, Li G, Ma X, Li R, Wang L, Xu Y, Zhou C, Lin X. Antipsychotic agents deteriorate brain and retinal function in schizophrenia patients with combined auditory and visual hallucinations: A pilot study and secondary follow-up study. Brain Behav 2020;10:e01611. [PMID: 32285647 DOI: 10.1002/brb3.1611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
72 Bryll A, Skrzypek J, Krzyściak W, Szelągowska M, Śmierciak N, Kozicz T, Popiela T. Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia. Biomolecules 2020;10:E384. [PMID: 32121669 DOI: 10.3390/biom10030384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]